The clinical practice guideline on diagnosis and treatment of hyponatraemia: A response from Otsuka pharmaceutical Europe Ltd

European Journal of Endocrinology

Volumn 171, Issue 1, 2014, Pages

  Avila, Marco ^a  

^a Otsuka Pharmaceutical Europe Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONIVAPTAN; LIXIVAPTAN; LOOP DIURETIC AGENT; PLACEBO; SATAVAPTAN; SODIUM CHLORIDE; TOLVAPTAN; UREA;

DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; FLUID THERAPY; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LETTER; LIVER TOXICITY; MONOTHERAPY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT DURATION;

FEMALE; HUMANS; HYPONATREMIA; MALE;

EID: 84903532738     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0392     Document Type: Letter

References (23)

1. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn E, Ichai C et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. European Journal of Endocrinology 2014 170 G1-G47. (doi:10.1530/EJE-13-1020)
2. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrology, Dialysis, Transplantation 2014 29 (Suppl 2) i1-i39. (doi:10.1093/ndt/gfu040)
3. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH & Thompson CJ. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. American Journal of Medicine 2013 126 S1-S42. (doi:10.1016/j.amjmed.2013. 07.006)
4. Runkle I, Navarro A, Pose A, Villabona C, Formiga F, Tejedor A & Poch E. El tratamiento de la hiponatremia secundaria al síndrome de secreción inadecuada de la hormona antidiurética. Medicina Clínica 2013 141 507.e1-507.e10. (doi:10.1016/j.medcli. 2013.09.002)
5. Chantzichristos D, Drougge H, Dahm P, Edén Engström B, Ekman B, Höybye C, Manhem P, Olsson T, Rask E, Öhlin B & Johannsson G. Vårdprogram för hyponatremi. Gothenburg, Sweden: Svensk Förening för Anestesi och Intensivvård & Svenska Endokrinolog Föreningen; 2012. Available at: http://endokrinologforeningen.se/documents/ Svenskt%20vardprograQ7m%20for%20hyponatremi-120120.pdf
6. Grossman A, Thatcher N, Bouloux P, Grant P, Cohen M, Murray R, Rees A, Ayuk J & Cranston I. Expert Panel Guidelines for the Treatment of Hyponatraemia (Draft version, presented at Stratford, UK, February 7th-8th 2013).
7. Otsuka Pharmaceutical Europe Ltd. Samsca (tolvaptan) summary of product characteristics. European Medicines Agency; 2014.
8. Otsuka America Pharmaceutical, Inc. Samsca (tolvaptan) prescribing information 2014.
9. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn EJ, Ichai C et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrology, Dialysis, Transplantation 2014 29 (10 Suppl 2) i1-i39. Supplementary appendix 6. (doi:10.1093/ndt/gfu040)
10. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, Decaux G, Fenske W, Hoorn E, Ichai C et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. European Journal of Endocrinology 2014 170 G1-G47. Supplementary appendix 6. (doi:10.1530/EJE-13-1020)
11. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, Czerwiec FS & SALT Investigators. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. European Journal of Endocrinology 2011 164 725-732. (doi:10.1530/EJE-10-1078)
12. Otsuka Pharmaceutical Europe Ltd. Tolvaptan pooled exposure data. Data on file: Periodic Update Safety Report July 2013. Wexham, Bucks, UK; Otsuka Pharmaceutical Europe Ltd: 2013.
13. Malhotra I, Gopinath S, Janga KC, Greenberg S, Sharma SK & Tarkovsky R. Unpredictable nature of tolvaptan in treatment of hypervolemichyponatremia: case review on role of vaptans. Case Reports in Endocrinology 2014. (doi:10.1155/2014/807054)
14. Otsuka Pharmaceutical Europe Ltd. Tolvaptan liver safety data. Data on file. Wexham, Bucks, UK; Otsuka Pharmaceutical Europe Ltd: 2014.
15. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS & SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. Journal of the American Society of Nephrology 2010 21 705-712. (doi:10.1681/ASN. 2009080857)
16. Rosner MH & Dalkin AC. Electrolyte disorders associated with cancer. Advances in Chronic Kidney Disease 2014 21 7-17. (doi:10.1053/j.ackd. 2013.05.005)
17. Castillo JJ, Vincent M & Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist 2012 17 756-765. (doi:10.1634/theoncologist.2011-0400)
18. Decaux G, Andres C, Gankam-Kengne F & Soupart A. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Critical Care 2010 14 R184. (doi:10.1186/cc9292)
19. Decaux G. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by long loop diuretics. Nephron 1983 35 82-88. (doi:10.1159/000183052)
20. Forssell G, Nordlander R & Orinius E. Treatment of dilutional hyponatremia in congestive heart failure. Acta Medica Scandinavica 1980 207 279-281. (doi:10.1111/j.0954-6820.1980.tb09721.x)
21. Castello L, Pirisi M, Sainaghi PP & Bartoli E. Quantitative treatment of the hyponatremia of cirrhosis. Digestive and Liver Disease 2005 37 176-180. (doi:10.1016/j.dld.2004.10.008)
22. Hantman D, Rossier B, Zohlman R & Schrier R. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline. Annals of Internal Medicine 1973 78 870-875. (doi:10.7326/0003- 4819-78-6-870)
23. Van Biesen W & Vanholder R. Clinical Practice Guideline on diagnosis and treatment of hyponatraemia: a response to letter from Otsuka Ltd. European Journal of Endocrinology 2014 171 L5. (doi:10.1530/EJE-14-0393)